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and in vitro confirmation, we identified 127 MHC ligands 
and analyzed the T-cell responses against these ligands 
via the MHC multimer-based enrichment of peripheral 
blood from 39 melanoma patients and 10 healthy donors. 
To dissect the T-cell reactivity against this large peptide 
library, we used combinatorial-encoded MHC multim-
ers and observed the T-cell responses against 17 different 
peptide-MHC complexes in the patient group and four in 
the healthy donor group. We confirmed the processing and 
presentation of HLA-A3-restricted T-cell epitopes from 
tyrosinase (TQYESGSMDK) and gp100 (LIYRRRLMK) 
and an HLA-A11-restricted T-cell epitope from gp100 
(AVGATKVPR) via the cytolytic T-cell recognition of mel-
anoma cell lines and/or K562 cells expressing the appro-
priate antigen and HLA molecule. We further found T-cell 
reactivity against two of the identified sequences among 
tumor-infiltrating lymphocytes from melanoma patients, 
suggesting a potential clinical relevance of these sequences.
Keywords T-cell epitope mapping · HLA-A2 negative · 
Melanoma · MHC multimer · Combinatorial encoding
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Abstract Immune therapy has provided a significant 
breakthrough in the treatment of metastatic melanoma. 
Despite the remarkable clinical efficacy and established 
involvement of effector CD8 T cells, the knowledge of the 
exact peptide-MHC complexes recognized by T cells on the 
tumor cell surface is limited. Many melanoma-associated 
T-cell epitopes have been described, but this knowledge 
remains largely restricted to HLA-A2, and we lack under-
standing of the T-cell recognition in the context of other 
HLA molecules. We selected six melanoma-associated 
antigens (MAGE-A3, NY-ESO-1, gp100, Mart1, tyrosi-
nase and TRP-2) that are frequently recognized in patients 
with the aim of identifying novel T-cell epitopes restricted 
to HLA-A1, -A3, -A11 and -B7. Using in silico prediction 
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Mart1  Melanoma antigen recognized by T cells 1
NY-ESO-1  New York Esophagus antigen 1
PBMCs  Peripheral blood mononuclear cells
PD1  Programmed death 1
PD-L1  Programmed death ligand 1
PE  Phycoerythrin
PE-Cy  Phycoerythrin–cyanin
PE-CF  Phycoerythrin–cyanin-based fluorescent dye
PerCp  Peridinin chlorophyll
Qdot  Quantum dot
R10  RPMI supplemented with 10 % FCS
TIL  Tumor-infiltrating lymphocyte
TRP-2  Tyrosinase-related protein 2
Introduction
Immune therapy of metastatic melanoma has provided 
promising clinical results with both long-lasting objec-
tive responses and the prolongation of overall survival. 
The major breakthroughs are based on blocking inhibitory 
immune-modulating pathways by inhibiting CTLA4 (cyto-
toxic T-Lymphocyte antigen-4), PD1 (programmed death 
1) and PD-L1 (programmed death ligand 1) [1–5]. Further-
more, adoptive cell therapy (ACT) has shown remarkable 
clinical results, and the implementation of this treatment 
strategy has spread to several institutions world-wide [6–
10]. Although the clinical efficacy of these trials is note-
worthy, the characterization of the molecular interactions 
responsible for tumor cell recognition has been limited. We 
previously analyzed tumor-infiltrating lymphocyte (TIL) 
cultures used for ACT for the recognition of all known 
melanoma-associated T-cell epitopes restricted to human 
leukocyte antigen (HLA)-A1, -A2, -A3, -A11 and -B7 [11]. 
We generated a database of 323 described melanoma-asso-
ciated T-cell epitopes and found that 45 % of these epitopes 
are restricted to HLA-A2. The remaining epitopes are dis-
tributed on 36 different HLA molecules, and the only other 
well-represented HLA molecule is HLA-A24. Thus, only 
a few T-cell epitopes have been identified for each of the 
remaining HLA molecules, which limit our understanding 
of T-cell recognition in melanoma on a broad population 
basis.
A number of melanoma-associated antigens are fre-
quently recognized in the context of HLA-A2, including 
gp100 (glycoprotein 100), Mart1 (melanoma antigen recog-
nized by T-cells 1), NY-ESO-1 (New York Esophagus anti-
gen 1), tyrosinase, TRP-2 (tyrosinase-related protein 2) and 
some MAGE (melanoma-associated antigen) proteins [11, 
12]. The MAGE proteins show considerable sequence simi-
larity, and most T-cell epitopes have been described from 
MAGE-A3 [11]. Thus, we selected this protein together 
with the above-mentioned proteins for this T-cell epitope 
mapping study. Gp100, tyrosinase and TRP-2 are involved 
in melanin synthesis [13–15], while Mart1 has been found 
necessary for gp100 function [16], and these proteins are 
expressed in most melanocytes and melanomas [17–19]. 
Furthermore, MAGE-A3 and NY-ESO-1 are widely 
expressed in advanced melanomas [20, 21] and selectively 
expressed in immune-privileged sites and cancers. To iden-
tify novel T-cell epitopes within the amino acid sequence 
of these antigens, we used a high-throughput T-cell epitope 
mapping platform [22]. This platform incorporates the pro-
duction of peptide-MHC (major histocompatibility com-
plex) reagents via the UV light-induced cleavage of condi-
tional ligands [23–25], and the detection of T-cell responses 
via combinatorial-encoded fluorochrome-coupled MHC 
multimers [26, 27]. Tumor-associated antigen-specific T 
cells are rare, and we therefore included an MHC multimer-
based T-cell enrichment step prior to detection. The paral-
lel enrichment of up to 400 different specificities is feasible 
[28], and thus, the method is well suited for the detection 
of rare T-cell responses in epitope mapping strategies [29].
We successfully identified 17 different CD8 T-cell 
responses within the peripheral blood from melanoma 
patients, T cells recognizing four of these were addition-
ally found in the blood from healthy donors. In addition, 
we screened TIL cultures from 30 melanoma patients with 
MHC multimers and detected three specific T-cell popula-
tions recognizing two of the 17 peptide-MHC complexes. 
Furthermore, we confirmed the processing and presentation 
on the surface of target mRNA-electroporated, HLA-trans-
duced K562 cells for two peptides restricted to HLA-A3 
and one to HLA-A11. For one T-cell specificity, moreo-
ver, we demonstrated the specific killing of a melanoma 
cell line that could be inhibited by adding cold target cells. 
The identification of these new T-cell epitopes will provide 
better tools for immunological monitoring and enable the 
antigen-specific targeting in HLA-A2-negative individuals.
Material and methods
Patient and healthy donor samples
Peripheral blood mononuclear cells (PBMCs) were col-
lected from melanoma patients and healthy donors. The 
blood samples were drawn a minimum of 4 weeks after the 
termination of anticancer therapy. The PBMCs were iso-
lated using Lymphoprep (Stemcell Technologies, Grenoble, 
France) separation, HLA typed (Department of Clinical 
Immunology, University Hospital, Copenhagen, Denmark) 
and frozen in fetal calf serum (FCS, from Gibco, Life 
Technologies, Naerum, Denmark) with 10 % dimethylsul-
foxide (Sigma-Aldrich, Broendby, Denmark). All materi-
als used were collected following approval by the Ethics 
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Committee for The Capital Region of Denmark and con-
ducted in accordance with the provisions of the Declaration 
of Helsinki.
MHC ligand prediction
NetMHC 3.0 Server [30–32] and NetMCHpan 2.1 Server 
[33, 34] predicted 9- and 10-mer ligands from the amino 
acid sequence of the proteins MAGE-A3 (Accession num-
ber NM_005362.3), NY-ESO1 (NM_001327.2), gp100 
(NM_006928.4), tyrosinase (NM_000372.4) and TRP-2 
(NM_001922.3) for binding to HLA-A1, -A3, -A11 and 
-B7. Peptides with a predicted IC50 < 1,000 nM in both 
servers were purchased and evaluated further.
UV light-mediated peptide exchange and MHC ELISA
Heavy and light chains were produced in Escherichia coli 
and refolded with a conditional ligand, which was substi-
tuted with a peptide of interest upon exposure to UV light 
(1 h, 366 nm) [23, 24]. To evaluate the affinity of the pre-
dicted ligands, the rescue of MHC monomers after UV-
induced peptide exchange was analyzed in a sandwich 
ELISA as previously described [23]. Virus-derived con-
trol ligands, HLA-A1/cytomegalovirus (CMV) pp65YSE, 
HLA-A3/influenza NPILR, HLA-A11/Epstein-Barr Virus 
EBNA4AVF and HLA-B7/CMV pp65RPH and a sample not 
exposed to UV light were used as positive controls; a sam-
ple without the rescue peptide was used as a negative con-
trol. Positive control peptides were tested in quadruplicate, 
and negative controls and test peptides were examined in 
duplicate. All measurements were repeated, and the absorb-
ance values for test peptides were normalized to control 
ligands. The selection thresholds are provided in the Sup-
plementary Figure 1. Peptides were purchased from Pep-
scan Ltd., NL.
MHC multimer-based enrichment and combinatorial 
encoding of MHC multimers
Peptide-MHC monomers were multimerized with phy-
coerythrin (PE)-streptavidin (Biolegend, Nordic Biosite, 
Copenhagen, Denmark) for MHC multimer-based T-cell 
enrichment. Briefly, the cells were thawed in 11 ml of 
RPMI, 10 % FCS (R10) (both from Gibco, Life Technolo-
gies, Naerum, Denmark), 25 U/ml DNase (Invitrogen, Life 
Technologies, Naerum, Denmark) and 2.27 mM MgCl2 
(Apoteket, Herlev University Hospital, Herlev, Denmark). 
1 ml of the cell suspension was irradiated at 25 Gy, washed 
twice and used as feeder cells. The remaining cells were 
resuspended in 100 μl R10, pooled PE-coupled MHC mul-
timers were added (0.1 μg/specificity based on MHC com-
plex alone) and the mixture was incubated at 4 °C for 1 h. 
After careful washing, 20 μl of α-PE beads (Dynabeads 
Magnetic Beads, Life Technologies, Naerum, Denmark) 
were added and the cells were left at 4 °C for 15 min, 
washed, resuspended in 500 μl R10 and applied to MS 
separation columns (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. 
The trapped cells were flushed out, counted and cultured 
at 37 °C and 5 % CO2, in a 96-well plate (Corning Costar, 
BD Biosciences, Albertslund, Denmark); each well con-
tained 5,000 positive fraction cells; 50,000 irradiated feeder 
cells; 11,000 CD3/CD28 activation beads (Dynabeads® 
Human T-Activator CD3/CD28 for T-cell Expansion and 
Activation, Life Technologies, Naerum, Denmark); IL-2 
(100 IU/ml, Proleukin, Novartis Healthcare, Copenhagen, 
Denmark) and IL-15 (23.8 IU/ml, Peprotech Nordic, Stock-
holm, Sweden) [28, 35]. The medium was refreshed every 
1–3 days.
After 2–3 weeks of culturing, we tested the cultures 
for T-cell populations recognizing the peptide-MHC com-
plexes used for enrichment via staining with combina-
torial-encoded MHC multimers, as described [26, 27]. In 
short, MHC monomers were multimerized with two dif-
ferent streptavidin conjugates for each peptide specific-
ity, enabling the simultaneous testing of 36 different spe-
cificities in a single sample by combining nine colors into 
dual-color codes for MHC multimers, in order to measure 
specific T-cell populations with flow cytometry. The cells 
were additionally stained with LIVE/DEAD® Fixable 
Near-IR Dead Cell Stain Kit for 633 or 635 nm excitation 
(Invitrogen, Life Technologies, Naerum, Denmark), CD8-
Alexa Flour 700 (BD Pharmingen, Albertslund, Denmark) 
or CD8-peridinin chlorophyll (PerCP) (Invitrogen, Life 
Technologies, Naerum, Denmark) and fluorescein isothio-
cyanate (FITC) coupled antibodies to CD3 or to a panel 
of CD4, CD14, CD16, CD19 (all from BD Pharmingen, 
Albertslund, Denmark) and CD40 (AbD Serotec, Puch-
heim, Germany). We used the following streptavidin-conju-
gated fluorochromes to detect the MHC multimer-specific 
T cells: PE, allophycocyanin (APC), phycoerythrin–cya-
nin (PE-Cy)7, phycoerythrin-cyanin-based fluorescent dye 
(PE-CF) 594, Brilliant Violet (BV)421, BV510, BV605, 
BV650 (all from BioLegend, Nordic Biosite, Copenhagen, 
Denmark), Quantum dot (Qdot) 585, Qdot 605, Qdot 625, 
Qdot 655 and Qdot 705 (all from Invitrogen, Life Tech-
nologies, Naerum, Denmark). The data were acquired on 
an LSR II flow cytometer, and the gating strategy is pro-
vided in Supplementary Figure 2. Virus-derived epitopes 
were included as positive controls for the specificity test-
ing but not for the enrichment procedure. All enrichments 
were repeated (except for one HLA-A1 and one HLA-
B7 patient, due to lack of patient material), and all T-cell 
responses were confirmed in another two-color combina-
tion of MHC multimers.
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Sorting of specific T-cell populations
Specific T-cell populations were sorted by fluorescence-
activated cell sorting to obtain T-cell cultures with a high 
frequency of specific T cells. The cells were stained with 
two-color-coded MHC multimers generated as mentioned 
above, CD3-FITC (BD Pharmingen, Albertslund, Den-
mark) and CD8-PerCP (Invitrogen, Life Technologies, 
Naerum, Denmark). The cells were sorted on an Aria II 
cell-sorter at 500 cells/well or 3 cells/well into a 96-well 
plate (Corning Costar, BD Biosciences, Albertslund, Den-
mark) containing 100,000 irradiated PBMCs (a 1:1:1 mix 
from three donors), incubated over night with 2 μg/ml phy-
tohemagglutinin (PHA, Gibco, Life Technologies, Naerum, 
Denmark) in 100 μl of X-vivo 15 (Lonza, Vallensbaek, 
Denmark), 5 % human serum (Sigma-Aldrich, Broendby, 
Denmark), IL-2 (500 IU/ml, Proleukin, Novartis Health-
care, Copenhagen, Denmark)), IL-15 (23.8 IU/ml, Pepro-
tech Nordic, Stockholm, Sweden), IL-21 (30 ng/ml, Pepro-
tech Nordic, Stockholm, Sweden) and an antibody to CD3 
(OKT3, 0.03 μg/ml, eBioscience, AH Diagnostics, Aarhus, 
Denmark) and the cells were incubated at 37 °C in 5 % 
CO2. After 5 days, half of the medium was exchanged with 
X-Vivo 15 containing 5 % human serum, IL-2 (6,000 IU/
ml), IL-15 (23.8 IU/ml) and IL-21 (30 ng/ml).
Production of in vitro transcribed mRNA
cDNA encoding gp100, tyrosinase and TRP-2 was synthe-
sized and cloned into pSP73-SphA64 (kindly provided by 
Professor E Gilboa, Duke University Medical Center, Dur-
ham, NC) using 5`XhoI/3`PacI restriction (Geneart/Life 
Technologies, Regensburg, Germany). The plasmids were 
propagated in E. coli competent cells (Invitrogen, Paisley, 
United Kingdom) and purified as described previously 
[36]. Prior to serving as a DNA template for in vitro tran-
scription, all plasmids were linearized with SpeI restriction 
enzyme and purified using the Wizard DNA Clean-Up Sys-
tem (Promega, Oslo, Norway). The in vitro transcription 
was performed as previously described [36].
Electroporation of K562 cells
The HLA-transduced K562 cells (kindly provided by 
Mirjam M.H. Heemskerk, Leiden University Medical 
Centre, the Netherlands) were transfected as previously 
described [29] with minor modifications. Briefly, HLA-
transduced K562 cells were washed twice, resuspended in 
phosphate-buffered saline (Invitrogen, Life Technologies, 
Naerum, Denmark) and adjusted to a final cell density of 
4 × 107 cells/ml. The cell suspensions (400 μl) were pre-
incubated in a 2-mm gap electroporation cuvette for 5 min 
on ice. mRNA encoding melanoma-associated antigens, 
gp100: 5.7 μg; tyrosinase: 6.7 μg; TRP-2: 8.9 μg, was 
used to transfect HLA-transduced K562 cells using a 
BTX 830 square-wave electroporator (Harvard Apparatus, 
Holliston MA, USA). The electroporation settings were 
adjusted to 6 pulses at 560 V for 99 μs. After electropo-
ration, the K562 cells were transferred to preheated R10 
medium and rested for 1 h, 37 °C in 5 % CO2. The fol-
lowing cells were obtained: K562/HLA-A3/gp100, K562/
HLA-A3/tyrosinase, K562/HLA-A11/gp100 and K562/
HLA-B7/TRP-2. Reverse Transcriptase PCR confirmed the 
presence of mRNA after 4, 8 and 24 h of resting at 37 °C.
VITAL-Far Red cytotoxicity assay
This ‘in vivo/in vitro technique for assessing cell lysis’ 
(VITAL)-Far Red assay has been described elsewhere [37]. 
Briefly, HLA-transduced K562 cells electroporated with 
relevant mRNA were marked with 10 μM carboxyfluo-
rescein succinimidyl ester (CFSE, Invitrogen, Life Tech-
nologies, Naerum, Denmark) and incubated for 5 min at 
37 °C in 5 % CO2; these cells were used as positive target 
cells. Transduced and not electroporated K562 cells were 
marked with 5 μM Far Red (Invitrogen, Life Technologies, 
Naerum, Denmark) and incubated for 5 min at 37 °C in 5 % 
CO2; these cells were used as negative control cells. The 
target cells and negative control cells were mixed at a ratio 
of 1:1, 2,000 cells/well in total, in 100 µl R10 in a 96-well 
plate (Corning Costar, BD Biosciences, Albertslund, Den-
mark). Specific T cells (effector cells) were added at dif-
ferent ratios to this target cells mixture in 100 μl R10. The 
cytotoxicity against the positive target cells was measured 
relative to the cytotoxicity against the negative control cells 
in the same mixture after 48-h incubation at 37 °C in 5 % 
CO2. Also, a data point without the addition of the effector 
T cells was included. All measurements were performed in 
quadruplicate and repeated to confirm the data.
51Chromium-release cytotoxicity assay
To measure the 51Chromium-release, 5 × 105 target cells 
in 100 µl R10 were labeled with 51Cr (100 µCi; Amersham, 
Arlington Heights, IL) and pulsed with peptide at 37 °C 
for 1 h when indicated. The washed target cells were incu-
bated with effector cells at various effector/target ratios in 
96-well plates at 37 °C for 4 h before 100 µl of medium was 
aspirated and the 51Cr release counted in a gamma coun-
ter (Wallac Wizard 1470 Automatic Gamma Counter, Per-
kin Elmer). The maximum 51Cr release was determined in 
separate wells by adding 100 µl of 10 % Triton X-100, and 
the spontaneous release was determined by adding 100 µl 
of R10 to target cells only. The specific lysis was calcu-
lated using the following formula: [(experimental release—
spontaneous release)/(maximum release—spontaneous 
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release)] × 100. The target cells were melanoma cell lines 
FM3 (HLA-A3+gp100+) and FM28 (HLA-A3−gp100+).
Generation of TILs
A standard two-step protocol was applied for the genera-
tion of clinical grade TIL cultures from tumor fragments, as 
previously described [38].
Results
Mapping of HLA-restricted peptide ligands 
from melanoma-associated proteins
We predicted 9- and 10-mer peptide ligands for binding 
to HLA-A1, -A3, -A11 and -B7 from MAGE-A3, NY-
ESO-1, gp100, Mart1, tyrosinase and TRP-2 by combin-
ing the output from the prediction servers NetMHC [30–
32] and NetMHCpan [33, 34]; the threshold for selection 
was IC50 < 1,000 nM for both algorithms. This approach 
resulted in 249 potential ligands, shown in Supplementary 
Table 1. These peptides were evaluated experimentally 
for their binding affinity to the relevant HLA molecules, 
measured by MHC ELISA as the peptide-dependent MHC 
rescue after the UV light-mediated exchange of a condi-
tional ligand [23–25]. The peptides were selected based 
on their ability to stabilize HLA molecules in either of 
two independent experiments, and the number of predicted 
and confirmed ligands for each allele is shown in Fig. 1a; 
data on the binding affinity of each potential ligand is 
depicted in Supplementary Figure 1 with gray illustrating 
the selected ligands. From the 249 predicted HLA ligands, 
we selected 127 confirmed ligands for further assessment 
in T-cell recognition analyses. The protein distribution of 
these ligands is shown in Fig. 1b; differences between the 
numbers of predicted peptides reflect differences in the 
protein size.
Mapping of melanoma-associated T-cell responses
We used the library of 127 confirmed HLA ligands to 
screen the peripheral blood cells from 39 melanoma 
patients to detect specific T-cell populations. We included 
an MHC multimer-based enrichment step prior to the 
detection with the aim of enhancing the specific T-cell fre-
quency, as spontaneous tumor-associated T-cell responses 
are often scarce and predominantly expected to be below 
the threshold of the detection method [29]. We previously 
established the detection limit for the detection of specific 
T-cell responses by combinatorial-encoded MHC multim-
ers to be 0.002 % of the CD8 cells with at least 10 MHC 
multimer positive events [27]. We generated a library of 
PE-labeled peptide-MHC multimers and used relevant 
complexes based on the patients’ HLA type to positively 
select HLA multimer-binding T cells over a magnetic col-
umn via capture with anti-PE-coated magnetic beads. The 
cells were cultured for 2–3 weeks prior to the testing of 
specific peptide-MHC recognition by using combinatorial-
encoded MHC multimers [27]. Each culture was tested for 
the presence of T-cell populations specific for the peptides 
used for T-cell enrichment as well as two virus-derived 
T-cell epitopes for each HLA molecule. We confirmed 
all detected responses with another MHC multimer stain-
ing using a different color-code, as exemplified for one 
response in Fig. 2a, b.
A total of 27 T-cell populations recognizing 17 differ-
ent peptide sequences in complex with the appropriate 
HLA molecules from five of the six proteins were detected 
in the PBMCs from 39 patients. An overview of all T-cell 
Fig. 1  MHC ELISA affinity testing of in silico predicted ligands. 
Peptides were selected according to the measured absorbance related 
to the rescue of the specific peptide-MHC complex after UV light-
mediated peptide exchange. The absorbance level was calculated 
relative to a positive control virus-derived peptide and peptides were 
selected if this normalization value was higher than a given thresh-
old in one of two independent experiments. a Shows the number of 
predicted and confirmed ligands distributed according to HLA restric-
tion, and b shows the number of predicted and confirmed ligands dis-
tributed according to target the proteins
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responses is provided in Table 1 and dot plots of the dif-
ferent responses are provided in Supplementary Figure 3. 
The T-cell responses against any of the included sequences 
were detected in 20/39 patients (51 %), irrespectively of 
the patients’ HLA type. Differences in the protein size and 
number of HLA ligands from each protein hinder the direct 
comparison of the response rates, but overall we most fre-
quently detected responses against the TRP-2-derived pep-
tides (8/39 patients). In addition, the majority of recognized 
peptides stem from three of the differentiation antigens. No 
Mart1-specific responses were detected. Figure 2c shows 
the number of T-cell responses detected for each peptide/
protein. Figure 2d illustrates the number of responses 
in each patient according to HLA type, and it is evident 
that all HLA molecules are involved in the recognition of 
melanoma-associated peptides, but most responses were 
detected in conjunction with HLA-B7 with 14 responses in 
17 tested HLA-B7-positive patients.
We further assessed if these melanoma-associated T-cell 
responses could be detected directly ex vivo in patient 
PBMCs. We investigated nine patients for the presence of 
13 T-cell specificities, which were detected after the MHC 
multimer-based T-cell enrichment of their PBMC samples, 
including a number of more frequent responses, ranging from 
0.1 to 2.2 % of the CD8 T cells. However, no T-cell responses 
against melanoma-associated proteins were found in this 
screening, although we did observe T-cell responses against 
virus-derived peptides for 6/9 patients (data not shown). This 
indicates that PBMCs hold very low numbers of T cells rec-
ognizing these melanoma-associated T-cell epitopes and the 
T-cell enrichment strategy is therefore required for detection, 
as illustrated in Supplementary Figure 4a and b.
Fig. 2  Detection of immune responses after MHC multimer-
based enrichment. a, b Example of a confirmed response found 
with combinatorial encoding of MHC multimers detecting HLA-
A3 Gp100614-22 reactive T cells, after a PE-MHC multimer-based 
enrichment of PBMCs. a 0.004 % of 270,000 CD8 cells detected in 
the PE/BV421 MHC multimer combination. b 0.004 % of 510,000 
CD8 cells detected in the PE/APC MHC multimer combination. 
Only CD8 cells negative for all MHC multimer (gray) or specific 
for exactly two MHC multimers (black) are shown, the gating strat-
egy is provided in Supplementary Figure 2. c The total number of 
T-cell responses detected per peptide sequence, grouped according 
to their protein origin. d The total number of responses detected 
per patient, when plotted according to patients’ HLA type. Each dot 
represents one patient. e The sum of melanoma-associated MHC 
multimer-specific T cells detected for each patient/healthy donor. 
The dotted line represents the mean frequency of responses found 
in the heathy donor cohort+ 3*standard deviation. Responses with 
higher frequency in the patient cohort are: HLA-B7/gp100319-327, 
HLA-B7/gp10026-35 and HLA-B7/NY-ESO82-90; HLA-A1/MAGE-
A368-77 (2 responses); and HLA-A3/gp100614-22
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To investigate whether these T-cell responses would 
be selectively found in melanoma patients, we addition-
ally screened blood from 10 healthy donors via the MHC 
multimer-based enrichment for T-cell reactivity against 
any of the 17 peptide-MHC complexes found to be recog-
nized in patient blood. We found a total of six responses 
against 4 peptide-MHC complexes present in 5/10 healthy 
donors (Table 1, indicated by superscript letter a). There 
was no overall difference in the frequency of response 
between the two groups (20/39 melanoma patients and 
5/10 healthy donors). However, in the patient group, a 
number of individuals presented with a higher frequency 
of multimer-specific T cells than in the healthy donor 
group (Fig. 2e).
Recognition of endogenously processed tumor-associated 
antigens
We successfully sorted and short-term expanded T-cell 
populations specific for five different peptide sequences 
from gp100 (2), tyrosinase (1) and TRP-2 (2). These 
T-cell cultures were used to confirm the recognition and 
antigen processing using HLA-transduced and antigen 
mRNA-transfected K562 cells. We determined the T 
cell-mediated killing of target cells after co-culture with 
T cells using a VITAL-Far Red cytotoxicity assay. MHC 
multimer-specific T cells were added in increasing ratios 
to the number of antigen-transfected HLA-transduced 
K562 cells, and specific killing was measured relative to 
non-transfected HLA-transduced K562 cells. Three spe-
cific cultures recognizing HLA-A3/gp100614-622, HLA-
A3/tyrosinase325-334 or HLA-A11/gp10020-28 showed anti-
gen-specific and effector:target ratio-dependent killing of 
target cells (Fig. 3a–c). We were not able to obtain a func-
tional readout for the additional two cultures (Table 1). 
Additionally, we measured the T cell-mediated killing 
of melanoma cell lines, FM3 (HLA-A3+gp100+) and 
FM28 (HLA-A3−gp100+) via co-culturing with HLA-
A3-restricted gp100614-622-specific T cells (Fig. 3d). We 
observed the selective killing of the HLA-A3-positive 
melanoma cell line FM3, and this killing was specifically 
inhibited by cold target inhibition with the addition of 
T2-A3 cells pulsed with gp100614-622, whereas it was not 
affected by addition of T2-A3 cells pulsed with an irrel-
evant peptide (Fig. 3e). Furthermore, T2-A3 cells pulsed 
with gp100614-622 or tyrosinase325-334 were specifically 
killed by T cells with matching specificities (Supplemen-
tary Figure 5a and b, respectively).
Table 1  Information about 27 (17 different) T-cell responses detected in 39 melanoma patients
ND not determined, TIL tumor-infiltrating lymphocyte. Most TIL cultures were not HLA typed for HLA-B7
a
 T-cell specificities also detected in the healthy donor cohort
Protein Sequence Amino acid position Tissue-type restriction Detection rate Validation of epitope 
processing in electropo-
rated, HLA-transduced 
K562 cells
Detection of T-cell 
responses in TIL cul-
tures
MAGE-A3 ASSLPTTMNY 68–77 HLA-A1 4/17a ND 0/18
FVQENYLEY 250–258 HLA-A1 2/17 ND 0/18
NY-ESO1 GPESRLLEF 82–90 HLA-B7 3/18 ND 0
TRP-2 LMETHLSSK 505–513 HLA-A3 1/14 ND 0/16
SPLWWGFLL 2–10 HLA-B7 2/18 No 0
QPQFANCSV 173–181 HLA-B7 1/18 ND 0
TPGWPTTLL 466–474 HLA-B7 2/18 ND 2
WPTTLLVVM 469–477 HLA-B7 1/18 ND 0
RLRKGYTPLM 497–506 HLA-B7 1/18 No 1
Tyrosinase LLRWEQEIQK 215–224 HLA-A3 1/14 ND 0/16
SPASFFSSW 264–272 HLA-B7 1/18a ND 0
TPRLPSSADV 309–318 HLA-B7 1/18 ND 0
TQYESGSMDK 325–334 HLA-A3 1/14 Yes 0/16
Gp100 AVGATKVPR 20–28 HLA-A11 1/5 Yes 0/4
VPRNQDWLGV 26–35 HLA-B7 1/18a ND 0
APNTTAGQV 319–327 HLA-B7 1/18 ND 0
LIYRRRLMK 614–622 HLA-A3 3/14a Yes 0/16
Total number of responses 27 3
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Screening of immune reactivity in melanoma TILs
To further investigate the clinical relevance of the 17 T-cell 
specificities detected after MHC multimer-based enrich-
ment of PBMCs, we screened TIL cultures generated from 
30 melanoma patients (18 HLA-A1+, 16 HLA-A3+, 4 
HLA-A11+, 3 HLA-B7+ and 27 with unknown HLA-B7 
status) for the presence of T-cell populations, recogniz-
ing any of these or three virus-derived peptides (HLA-A1/
CMV pp50VTE, HLA-A3/CMV pp150VTT and HLA-B7/
Fig. 3  Recognition of processed antigen in K562 cells or mela-
noma cell lines. a Lysis of K562/HLA-A3/gp100 cells compared 
with K562/HLA-A3 cells when co-cultured with increasing num-
bers of HLA-A3 gp100614-622-specific T cells (60.0 % of CD8 cells) 
in the given specific effector/target cell ratio, determined as the ratio 
between MHC multimer positive T cells and K562/HLA-A3/gp100 
cells. b Lysis of K562/HLA-A3/tyrosinase cells compared with 
K562/HLA-A3 cells when co-cultured with increasing numbers of 
HLA-A3/tyrosinase325-334-specific T cells (81.7 % of CD8 cells) in 
the given effector:target cell ratio. c Lysis of K562/HLA-A11/gp100 
cells compared with K562/HLA-A11 cells when co-cultured with 
increasing amounts of an HLA-A1/gp10020-28-specific T-cell culture 
(51.8 % of CD8 cells) in the given effector/target cell ratio. d Chro-
mium-release cytotoxicity testing of the HLA-A3/gp100614-622 culture 
(60.0 % of CD8 cells) against gp100 positive and HLA-A3-positive 
(FM3) and HLA-A3-negative (FM28) melanoma cell lines. e Cyto-
lytic recognition of the FM3 melanoma cell line and cold target 
inhibition of gp100614-22-specific T cell-mediated killing with HLA-
A3-transduced T2 pulsed with either gp100614-22 or an irrelevant 
tyrosinase-derived peptide. Data shown in (a–c) were measured with 
the VITAL-Far Red assay after 48 h of co-culturing of effector and 
target cells at 37 °C, and data shown in (d, e) were obtained with a 
standard Cr51-release assay after 4 h of co-culturing of effector and 
target cells at 37 °C. Shown in all plots is the relative lysis of posi-
tive target cells. The effector/target ratio is calculated based on MHC 
multimer-specific effector T cells. Bars represent the standard devia-
tion of two independent experiments
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CMV pp65RPH). We detected melanoma-associated T-cell 
responses in three of these patients; two responses against 
HLA-B7/TRP-2466-474 and one against HLA-B7/TRP-
2497-506, in parallel with a total of 6 virus-specific T-cell 
responses (Fig. 4; Table 1). Thus, this extended cohort of 
melanoma-associated T-epitopes may add to our under-
standing of the tumor recognition element seen in mel-
anoma-infiltrating lymphocytes used for ACT. All the 
analyzed TIL cultures were generated for clinical use; how-
ever, only one of the three patients holding a TRP-2 T-cell 
response were treated with ACT; this patient experienced 
a partial response to therapy. None of these patients were 
included in the initial screening of the PBMC samples.
Discussion
Previously, T-cell epitope mapping studies in melanoma 
have focused on HLA-A2 and HLA-A24, and only few 
T-cell epitopes restricted to other tissue types have been 
published [11]. The knowledge obtained in this study, of 
T-cell reactivity against 17 different peptide sequences 
derived from MAGE-A3 (2), NY-ESO-1 (1), gp100 (4), 
tyrosinase (4) and TRP-2 (6), will help broadening the 
measurements of the T-cell repertoire restricted to HLA-
A1, -A3, -A11 and -B7, even though we have only formally 
confirmed a minority of these as T-cell epitopes.
We specifically assessed the processing and presentation 
for a part of these sequences and showed T-cell recogni-
tion on the surface of target mRNA-electroporated HLA-
transduced K562 cells for three of the five peptides tested. 
The processing and presentation of the remaining peptide 
sequences were not tested due to an insufficient number of 
specific T cells. However, we do anticipate based on the 
experience that the majority of these sequences will be pre-
sented on the cell surface. To fully confirm the processing 
and presentation for all peptides in Table 1, further cyto-
toxicity studies including sequence-specific inhibition are 
needed for the remaining 11 peptide sequences. HLA-A3/
gp100614-22-specific T cells further showed cytolytic activ-
ity toward a melanoma cell line in an HLA and protein-
specific manner. HLA-A3/Tyrosinase325-334 and HLA-A11/
gp10020-28 are newly identified T-cell epitopes, while HLA-
A3/gp100614-22 was published previously [39]. However, 
in this previous study, the T-cell recognition of HLA-A3/
gp100614-22 on the surface of melanoma cells was measured 
based on the secretion of interferon-γ and our study is the 
first to show the direct T cell-mediated killing of cells that 
present this epitope on the surface. The confirmation of this 
gp100-derived T-cell epitope also served as an internal con-
trol for our T-cell epitope mapping study. Additionally, it 
is one of the most frequently recognized responses in our 
study; we detected HLA-A3/gp100614-22-specific T cells in 
3/14 (21 %) tested HLA-A3 positive patients, suggesting 
its relevance as a broadly recognized melanoma-associated 
T-cell epitope.
A number of responses were also detected in the healthy 
donor cohort (Fig. 2e; Table 1), which likely relates to the 
self-origin of the analyzed peptide sequences, combined 
with the sensitivity of our detection method. Using the 
same methodology, we recently showed a complete lack 
of T-cell recognition of oncogenic proteins from the Mer-
kel cell polyoma virus in a healthy donor cohort, while 
these were frequently recognized in a Merkel cell carci-
noma cohort. Additionally, both cohorts harbored reactiv-
ity toward virus capsid proteins [29]. Hence, we believe 
the T-cell responses found in the current study originate 
from antigen-experienced cells potentially relevant in 
Fig. 4  T-cell responses in melanoma TILs detected by dual-color-
coded MHC multimers. a 0.41 % HLA-B7/TRP-2466-474-specific T 
cells of 609.000 CD8 cells detected with the BV421:BV650 MHC 
multimer combination. b 0.037 % HLA-B7/TRP-2466-474-specific T 
cells of 176.000 CD8 cells detected with the BV421:BV650 MHC 
multimer combination, c 0.017 % HLA-B7/TRP-2497-506-specific 
T cells of 366.000 CD8 cells detected with the PE:PE-CF594 MHC 
multimer combination. All responses were additionally confirmed 
using another two-color combination
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establishing anti-tumor reactivity and not from the naïve 
repertoire. Previously reactivity against melanoma-asso-
ciated differentiation antigens present in the blood from 
healthy donors has mainly been described in relation to 
the HLA-A2/Mart126-35 epitope [40]. Also Tyrosinase-
reactive T cells have previously been found in the blood 
from healthy donors [41], while spontaneous healthy donor 
CD8-mediated T-cell reactivity against gp100 and MAGE-
A3 has to our knowledge never been described before.
We did not detect any responses to peptides from the 
Mart1 protein, which is striking given the frequent detec-
tion of T cells specific for the HLA-A2/Mart126-35/27-35 
epitope, e.g., 21/30 melanoma TIL cultures in a previous 
study showed HLA-A2/Mart126-35/27-35 reactivity [11]. It 
has been shown that peptides overlapping this region could 
also be presented to T cells by HLA-B44, HLA-B45 and 
HLA-B35 molecules [42, 43], whereas the mapping of 
epitopes from other regions of the protein has failed to a 
large extent, with the exception of the identification of 
Mart151-61 as an HLA-Cw7-restricted epitope [44]. The 
exceptional high frequency of MART-126-35-reactive T cells 
in both patients and healthy individuals has been explained 
by a combination of a preferential pairing of the MART-
126-35 T-cell receptor [45], an excessive positive selec-
tion owing to the cross-reactivity to other self-antigens 
expressed in cortical thymic epithelial cells [46], and the 
mis-initiated transcription of MART-1 in medullary thymic 
epithelial cells resulting in inefficient negative selection 
[47].
We additionally screened TIL cultures from melanoma 
patients and found responses in three patients against two 
peptide sequences derived from TRP-2 and restricted to 
HLA-B7. The level of reactivity is comparable with our pre-
vious finding with mapping of T-cell reactivity in melanoma 
TILs toward a large panel of melanoma-associated T-cell 
epitopes [11, 12]. The response rate in our study, when 
calculated as the number of detected responses compared 
with the theoretical maximal number of responses ignor-
ing HLA-differences of the patient cohort (3 responses out 
of 17 peptides × 30 cultures), was 0.6 %, while in the pre-
vious study the similar number was 0.8 % [11]. However, 
this value included responses against the very frequently 
detected HLA-A2/Mart126-35(27L) epitope, and as mentioned 
above, the T-cell recognition of this epitope is special. If 
these responses are left out the response rate in the pre-
vious study also yields a value of 0.6 % [11]. Two of the 
TIL cultures holding a TRP-2 response in the present study 
where additionally screened using the larger peptide library 
(as in [11]), revealing additionally two responses. Thus, 
the present findings add to the notion that these peptides 
increase our understanding of antigen recognition in these 
cultures. Anti-tumor reactivity in expanded TILs is asso-
ciated with clinical benefit [48]; and selection of the TILs 
toward cancer-associated antigen-specific cells prior to infu-
sion may improve the clinical efficacy of this strategy. The 
extended repertoire of the relevant epitopes, as presented 
here, will broaden the possible implementation of such 
strategies, independent of patient’s HLA type, and extend 
our possibility to define the most essential T-cell epitopes.
Antibodies targeting CTLA4 and PD-1/PD-L1 have 
shown remarkable clinical efficacy in metastatic melanoma 
[1, 2, 5]. These therapies may depend on an existing endog-
enous immune response, and although anti-tumor immu-
nity can be stimulated in a subgroup of patients, we do not 
know to what extent the remaining patients harbor tumor-
reactive T cells. To select immunocompetent patients with 
preexisting immune responses that are more likely to 
respond clinically, comprehensive monitoring strategies, 
ideally covering the majority of HLA alleles expressed, are 
needed. The T-cell responses and epitopes we report here 
will contribute to a better understanding of anti-melanoma 
T-cell immunity and possibly enhance the new initiatives 
toward improved clinical efficacy of the immune therapeu-
tic treatment of metastatic melanoma.
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